R
Resolve
Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of single-cell spatial biology
About Resolve
Resolve Biosciences, a company focused on spatial biology, was founded in 2016. The company has developed a platform, Molecular Cartography™, that provides a high-resolution view of single-cell spatial biology.
The technology offers subcellular resolution, allowing scientists to gain insights from preserved tissue samples. The platform is designed to detect individual transcripts and rare signals with high sensitivity and specificity. This capability is particularly relevant for research in oncology, neuroscience, and infectious diseases.
Resolve Biosciences operates on a business model centered around providing access to its proprietary technology. The company is currently offering its platform through an oversubscribed early access program, indicating a strong market demand for its services. The clients are primarily scientists and researchers in the fields of oncology, neuroscience, and infectious disease who require detailed spatial analysis of biological tissues.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Monheim am Rhein, Germany
- Employees
- 69
- Open positions
- None listed
- Dealroom signal
- 69.9/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Hard Tech, DT and LS, science-based
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2022 | $71M | $284M | EDBI · NRW.BANK · Alafi Capital · PS Capital Partners | ↗ |
| SERIES AOther financing | Dec 2020 | $24M | $96M | Alafi Capital · PS Capital · HTGF · John Shoffner | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Resolve is 460 monthly website visits, down 67.1% over the last three months. Resolve's team declined 9.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
PS Capital- ACAlafi Capital
HTGF- JSJohn Shoffner
EDBI
NRW.BANK- PPPS Capital Partners
Patient Square Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Resolve on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Resolve’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.